Markets · 1 sources covering this

Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan Kulkarni

Indian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. Companies are investing in advanced research and development. Global regulatory changes favor Indian players. The market is not yet fully recognizing this innovation pivot and the quality of talent driving it. GLP-1 drugs and supply chain diversification also present substantial growth potential.

Share:WhatsApp X Reddit Facebook LinkedIn

Coverage spectrum

0 L · 0 C · 1 R

How 1 sources are covering this

Economic TimesLean R·2h ago
Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan Kulkarni
Indian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. Companies are investing in advanced research and development. Global regulatory changes favor Indian players. The market is not yet fully recognizing this innovation pivot and the quality of talent driving it. GLP-1 drugs and supply chain diversification also present substantial growth potential.
Read at Economic Times →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/5cde6673d529fa3148fe117d4ad76ded5615bd6d"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan Kulkarni"></iframe>

Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan Kulkarni

How 1 sources are covering this

Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan Kulkarni

More from Markets

Can Cera Sanitaryware’s growth recovery continue?

Arvind SmartSpaces eyes Rs 180 cr revenue from housing project in Ahmedabad

Rupee closes at 94.56 vs USD; US-Iran peace agreement details, Fed guidance awaited

Sensex extends bull run to third day on US-Iran peace deal, jumps 540 points: 10 key highlights from Indian stock market

Reader

Trust & legal

Across the network